

FIG. 1




FIG. 2A




FIG. 2B






FIG. 3




4/29

FIG. 4A




Ka (1/Ms): 6.33E+5 Kd (1/s): 1.69E-4
KD (M): 2.67E-10

FIG. 4B



Ka (1/Ms): 6.38E+5 Kd (1/s): 1.96E-4
KD (M): 3.07E-10



Ka (1/Ms): 1.37E+5 Kd (1/s): 7.60E-5
KD (M): 5.57E-10

6/29

FIG. 6A




FIG. 6B




FIG. 6C






FIG. 6D



8/29

FIG. 6E



9/29

FIG. 7A

HaCaT wild-type
IL-1 β stimulation





FIG. 7B

HaCaT wild-type
IL-36 γ stimulation



10/29

FIG. 8A

IL-1 β stimulation
IL-8 release





FIG. 8B


IL-12/IL-33 stimulation
IFN γ release



- Isotype control_4
- Anti-human IL-1RAP_candidate_1
- Isotype control_4 + sIL-1RAP
- Anti-human IL-1RAP_candidate_1 + sIL-1RAP

11/29

FIG. 9A



12/29

FIG. 9B





FIG. 9C



14/29

FIG. 9D




FIG. 10




FIG. 11
NIH-3T3




FIG. 12A
mIL-1b stimulation
mIL-6 release






FIG. 12B

hIL-33 stimulation
mIL-6 release



18/29

FIG. 12C



- Isotype control_2
- Anti-mouse IL-1RAP_candidate_1

FIG. 13




FIG. 14




FIG. 15




FIG. 16





FIG. 17



24/29

FIG. 18A





FIG. 18B




25/29

FIG. 18C



FIG. 18D



26/29

FIG. 18E



FIG. 18F




FIG. 18G





FIG. 19A



29/29

FIG. 19B

<i>Number of responder donors</i>	IL-6	IL-8	MCP-1	MIP-1alpha	MIP-1beta
IL-1 α Stimulation	13	11	10	8	10
IL-1 β Stimulation	15	15	10	10	11